Australian Clinical Labs Limited provides pathology services.
Australian Clinical Labs Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$4.29|
|52 Week High||AU$3.18|
|52 Week Low||AU$5.08|
|1 Month Change||-6.54%|
|3 Month Change||14.71%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||25.44%|
Recent News & Updates
The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Australian Clinical Labs Limited ( ASX:ACL ) just reported healthy earnings but the stock price didn't move much. Our...
|ACL||AU Healthcare||AU Market|
Return vs Industry: Insufficient data to determine how ACL performed against the Australian Healthcare industry.
Return vs Market: Insufficient data to determine how ACL performed against the Australian Market.
Stable Share Price: ACL is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: Insufficient data to determine ACL's volatility change over the past year.
About the Company
Australian Clinical Labs Limited provides pathology services. The company offers various routine pathology tests, advanced pathology, first trimester screening and non-invasive prenatal testing, chemical pathology, hematology, histopathology, immunology, serology and microbiology, functional pathology, and commercial drug and alcohol testing services. The company offers its service to private and public hospitals.
Australian Clinical Labs Fundamentals Summary
|ACL fundamental statistics|
Is ACL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACL income statement (TTM)|
|Cost of Revenue||AU$126.47m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Feb 24, 2022
|Earnings per share (EPS)||0.30|
|Net Profit Margin||9.34%|
How did ACL perform over the long term?See historical performance and comparison
Is Australian Clinical Labs undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACL (A$4.29) is trading below our estimate of fair value (A$35.65)
Significantly Below Fair Value: ACL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACL is good value based on its PE Ratio (14.3x) compared to the Australian Healthcare industry average (24.7x).
PE vs Market: ACL is good value based on its PE Ratio (14.3x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: ACL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ACL is overvalued based on its PB Ratio (10.6x) compared to the AU Healthcare industry average (2.2x).
How is Australian Clinical Labs forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACL's earnings are forecast to decline over the next 3 years (-15% per year).
Earnings vs Market: ACL's earnings are forecast to decline over the next 3 years (-15% per year).
High Growth Earnings: ACL's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ACL's revenue is expected to decline over the next 3 years (-2.1% per year).
High Growth Revenue: ACL's revenue is forecast to decline over the next 3 years (-2.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACL's Return on Equity is forecast to be low in 3 years time (19.9%).
How has Australian Clinical Labs performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACL has high quality earnings.
Growing Profit Margin: ACL's current net profit margins (9.3%) are higher than last year (8.4%).
Past Earnings Growth Analysis
Earnings Trend: ACL's earnings have grown significantly by 60.3% per year over the past 5 years.
Accelerating Growth: ACL's earnings growth over the past year (46.3%) is below its 5-year average (60.3% per year).
Earnings vs Industry: ACL earnings growth over the past year (46.3%) underperformed the Healthcare industry 61.3%.
Return on Equity
High ROE: Whilst ACL's Return on Equity (73.72%) is outstanding, this metric is skewed due to their high level of debt.
How is Australian Clinical Labs's financial position?
Financial Position Analysis
Short Term Liabilities: ACL's short term assets (A$117.2M) do not cover its short term liabilities (A$166.2M).
Long Term Liabilities: ACL's short term assets (A$117.2M) do not cover its long term liabilities (A$226.6M).
Debt to Equity History and Analysis
Debt Level: ACL's debt to equity ratio (121.3%) is considered high.
Reducing Debt: Insufficient data to determine if ACL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ACL's debt is well covered by operating cash flow (154.9%).
Interest Coverage: ACL's interest payments on its debt are well covered by EBIT (8.5x coverage).
What is Australian Clinical Labs's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ACL is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Melinda McGrath is Chief Executive Officer and Executive Director at Australian Clinical Labs Limited since December 19, 2020. She served as Chief Executive Officer and Executive Director at Clinical L...
CEO Compensation Analysis
Compensation vs Market: Melinda's total compensation ($USD1.79M) is above average for companies of similar size in the Australian market ($USD973.44K).
Compensation vs Earnings: Melinda's compensation has been consistent with company performance over the past year.
Experienced Management: ACL's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: ACL's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: ACL only recently listed within the past 12 months.
Australian Clinical Labs Limited's employee growth, exchange listings and data sources
- Name: Australian Clinical Labs Limited
- Ticker: ACL
- Exchange: ASX
- Founded: 2020
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$865.868m
- Shares outstanding: 201.83m
- Website: https://www.clinicallabs.com.au
Number of Employees
- Australian Clinical Labs Limited
- 1868-1892 Dandenong Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 15:39|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.